1577 - Real-World, Multicenter Experience with Eravacycline for Various Infections

The ePoster content is available to users who are logged in.<br><br>Please log in and then come back here to use this button.

Presenting Author(s)

Sara Allosaimy

Research Scientist
Wayne State
Detroit, Michigan
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Co-Author(s)

AL

Abdalhamid M. Lagnf

Research Assistant
Anti-Infective Research Laboratory; Wayne State University
Detroit, Michigan
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
KM

Kyle C. Molina

Clinical Pharmacy Specialist Infectious Diseases
University of Colorado Hospital
Aurora, Colorado
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
MK

Madeline King

Assistant Professor
Cooper University Hospital
Camden, New Jersey
Disclosure: Tetraphase (Speaker's Bureau)
BP

Benjamin Pullinger

assistant Professor
University of the Sciences
Philadelphia, Pennsylvania
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
ST

Serina Tart

Clinical Pharmacist
Cape Fear Valley Health
Fayetteville, North Carolina
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Bruce M. Jones

Infectious Diseases Clinical Pharmacy Specialist
St. Joseph's/Candler Health System
Savannah, GA
Disclosure: ALK-Abello (Research Grant or Support)Allergan/Abbvie (Speaker's Bureau)
Kimberly C. Claeys

Associate Professor
University of Maryland Baltimore
Baltimore, MD
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
JT

James Truong

Clinical Pharmacy Coordinator, Infectious Diseases
Brooklyn Hospital
Brooklyn, New York
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Justin A. Andrade

Infectious Diseases Pharmacy Fellow
The Brooklyn Hospital Center
Brooklyn, New York
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
MB

Mark Biagi

Infectious Diseases Pharmacotherapy Fellow
Swedish American Hospital
Rockford, Illinois
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
MP

Michael Pierce

Pharmacy resident
Swedish American Hospital
Rockford, Illinois
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Reese Cosimi

Clinical Pharmacist
Ascension
Indianapolis, Indiana
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
AH

Athena L. V. Hobbs

Infectious Diseases Clinical Pharmacy Specialist
Baptist Memorial Hospital-Memphis
Memphis, TN
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
NP

Nicholas Perkins

Pharmacy student
Baptist Memorial Hospital
Memphis, Tennessee
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
GH

Glen Huang

Fellow
University of California - Los Angeles
Los Angeles, California
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
MV

Michael Veve

Clinical Pharmacy Specialist, Infectious Diseases
University of Tennessee Medical Center
Knoxville, TN
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
TM

Taylor Morrisette

Postdoctoral Research Fellow
Wayne State University
Detroit, Michigan
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Susan L. Davis

Clinical Professor and Associate Dean for Pharmacy
Wayne State University
Detroit, Michigan
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
MR

Michael J. Rybak

Professor
Eugene Applebaum College of Pharmacy and Health Sciences
Detroit, Michigan
Disclosure: Paratek (Grant/Research Support)

Background: Eravacycline (ERV) is Food and Drug Administration approved in patients for the treatment of adults complicated intra-abdominal infections in 2018. Real-world data regarding the indications for ERV use are is limited. We evaluated the clinical/safety outcomes of patients treated with ERV in FDA and non-FDA approved indications.

Methods: Multicenter, retrospective, observational study from September 2018 to June 2020. Adult patients treated with ERV for ³ 72 hours were included. The primary outcome was 30-day survival. Secondary outcomes included a lack of 30-day infection-recurrence, resolution of signs/symptoms of infection and safety. All outcomes were measured from ERV start date.

Results: Overall, 108 patients were included from 12 geographically-distinct medical centers across the United States. The median(IQR) age was 60(52-67) years and 60% were male. Median(IQR) APACHE II and Charlson Comorbidity scores were 15(11-21) and 3 (2-6), respectively. The most common sources of infection were intra-abdominal (32%), and respiratory (24%). Common pathogens included Acinetobacter baumannii (19%), Klebsiella pneumoniae and Enterococcus faecium (16%). Infectious diseases consultation was obtained in 98%, and surgical interventions in 51% of cases. Patients often received active therapy prior to ERV(40%). Median(IQR) ERV therapy duration was 7.7(4.4-14.0) days. Among cases with documented cultures, ERV was initiated within a median(IQR) of 4.8(2.5-9.9) days. Combination therapy ³ 48 hours was given in 45%. The primary endpoint was achieved in 79%(85/108). Of patients who died(n=23), 57% were on monotherapy, 39% were critically ill, 39% had intra-abdominal as a source, and 30% had positive blood cultures. For secondary outcomes, 94%(102/108) lacked 30-day infection-recurrence and 74%(80/108) resolved signs/symptoms of infection. ERV was selected primarily for consolidation of the regimen(40%). Eight patients experienced a probable ERV-related adverse event, mainly gastrointestinal(87.5%) and none experienced clostridium difficile.

Conclusion: 30-day survival was achieved in the majority of patients treated with ERV. Studies with longer follow-up are required to confirm these findings.